NEU 1.00% $18.83 neuren pharmaceuticals limited

Ann: DAYBUE net sales US$87.1 million in Q4 2023, page-64

  1. 1,488 Posts.
    lightbulb Created with Sketch. 116
    So, really rough calculations.

    Cash: 228m (as of last 4c)
    Daybue Royalties: 65m (Mid-point) - 35x fwd PE - 2,227m)
    PRV 1/3 -33m USD, 50m AUD
    Daybue Milestones:
    >250m 50M USD (75m aud) - Guidance $370 - 420m - easily hit

    Only the above things (that are known) can give a conservative 2.5b market cap. What isn't included (I have probably missed some, too)

    • Milestone for >500m (50m USD)
    • Milestone for >750m (100m USD)
    • Milestone for >1b (150m USD)
    • MIlestone related to Fragile X development, if it goes ahead (55m USD)
    • Value for the NNZ-2556 successful P2 in PMS
    • Any other NNZ-2256 trial
    • Row Milestone (100m usd upfront, 35m usd for first sale in europe, 15m usd for japan, 10m for a second indication in europe, 4m for a second indication in japan)
    • Royalites for Daybue (Row) - Mid teens to low 20% of net sales
    • Sales milestones based on Daybue Row Sales
    • Future indications for NNZ-2256

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$18.83
Change
-0.190(1.00%)
Mkt cap ! $2.401B
Open High Low Value Volume
$18.96 $19.06 $18.72 $2.871M 152.4K

Buyers (Bids)

No. Vol. Price($)
6 386 $18.83
 

Sellers (Offers)

Price($) Vol. No.
$18.85 73 5
View Market Depth
Last trade - 13.23pm 12/06/2024 (20 minute delay) ?
Last
$18.82
  Change
-0.190 ( 0.02 %)
Open High Low Volume
$18.95 $19.02 $18.72 56217
Last updated 13.42pm 12/06/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.